WHO ICTRP trial
Phase II clinic trial for the reduction of time of hematopoietic stem cell…
EUCTR2008-005042-23-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-005042-23-IT |
|---|---|
| Public title | Phase II clinic trial for the reduction of time of hematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation - ND |
| Scientific title | Phase II clinic trial for the reduction of time of hematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation - ND |
| Primary sponsor | AZIENDA OSPEDALIERA PISANA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Italy |
| Conditions | patients affected by multiple myeloma requiring chemotherapy with high-dose melphalan (100 mg/m2). MedDRA version: 9.1 Level: LLT Classification code 10028228 Term: Multiple myeloma |
| Interventions | Trade Name: JANUVIA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: SITAGLIPTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- |
| Registration date | Oct 17, 2008 |
| Secondary IDs | 2538/2008 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: